About Ceftobiprole
About Ceftobiprole
Ceftobiprole is an anti-MRSA, broad-spectrum cephalosporin that has demonstrated positive results in two phase III trials in complicated skin and skin structure infections. Ceftobiprole has shown a low potential to select for resistance in vitro and exhibits in vitro activity against a wide spectrum of bacteria that cause many hospital and community-acquired infections including those due to resistant bacteria like methicillin-resistant Staphylococcus aureus (MRSA). Ceftobiprole has received fast track status from the FDA and is being developed through an exclusive worldwide collaboration between Basilea Pharmaceutica Ltd. and Cilag GmbH International, a Johnson & Johnson affiliate.
http://www.medilexicon.com/medicalnews.php?newsid=60549
